Skip to main content

A trader works on the floor of the New York Stock Exchange, April 10, 2012.

BRENDAN MCDERMID/Brendan McDermid/Reuters

Canadian issues that are moving on early news.

Sprott Power Corp. reported revenues of $4-million for the second quarter of 2012. This compares with revenues of $2.5-million for the same three month period in 2011, an increase of $1.5 or 60 per cent. The net loss attributable to the shareholders was $0.016, compared with $0.021 in the same period in 2011.

Medicago Inc., which gained six per cent yesterday, announced that it has achieved a key milestone with the production of at least 10 million doses of H1N1 VLP influenza vaccine candidate in one month. This rapid fire test was conducted at Medicago's facility in Durham, North Carolina.

Story continues below advertisement

Cornerstone Capital Resources Inc. has entered into a joint venture with SolGold PLC for an aggressive first year exploration program totalling $2.8-million (U.S.) for the Cascabel gold-copper-silver property. CGP closed at 11 cents yesterday.

Red Eagle Mining Corporation, which rose nearly two per cent yesterday, announced additional assay results received from the 24 hole, 5,400-metre phase two core drill program at the San Ramon gold system located within the Santa Rosa gold project. The additional results show strong gold mineralization over significant intervals.

CIC Energy announced an all-cash offer from Jindal Steel & Power for $2.00 per share. The board recommended acceptance by CIC Energy shareholders.

Pure Industrial Real Estate Trust, which is trading at year high levels, announced it has entered into an agreement to acquire a fully leased multi-tenant, income producing industrial property for a total purchase price of $4.25-million.

Mirabela Nickel Limited announced its unaudited second-quarter results. Highlights include the production of 4,276 tonnes of nickel in concentrate, compared with 4,245 tonnes in the first quarter of 2012, and sales of 4,787 tonnes of nickel in concentrate, up 15 per cent from 4,155 tonnes in the first-quarter of 2012.

David Cutler has been appointed president and chief executive officer of Centric Health Corporation, a diversified health-care services company that saw its shares drop 7.5 per cent on Monday. Mr. Cutler, who will assume his responsibilities in September 2012, joins from Leisureworld Senior Care Corporation.

Bioniche Life Sciences Inc., which lost five per cent Monday, announced that Immunocidin, the first of two canine oncology products, has received approval by regulators in both the U.S. and Canada. Market launch activities are currently underway with an expectation to have Canadian product available in September, 2012, followed by a U.S. launch before the end of the calendar year.

Story continues below advertisement

Alphinat Inc., which is trading near year lows, said net loss for the first quarter was $157,213 or $0.003 per outstanding common share compared with a net loss of $305,467 or $0.006 per outstanding common share for the corresponding period in 2011.

Report an error Editorial code of conduct
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies